ArticleEuropean journal of medical research2025
Up-regulating methylation of CAP1 promoter can promote apoptosis and inhibit migration and invasion of lung adenocarcinoma cells.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer, which poses a significant threat to human health. Adenylate cyclase-associated protein 1 (CAP1) is an important protein closely linked to cancer initiation and progression.
methodTarget Gene fragments were amplified by PCR, and the products of 2 fragments were ligated to construct pdCas9-Dnmt3a-BSD plasmid. Stable cell lines with methylation of CAP1 promoter up-regulated were then established through transfection and screening. Cell proliferation was assessed using colony formation and proliferation assays, while apoptosis was assessed by flow cytometry. Wound healing, transwell migration, and invasion assays were conducted to evaluate cell migration and invasion. Western blot and PCR assays were used to study the expression of molecules involved in apoptosis, migration, and invasion.
resultCAP1 protein expression was higher in early-stage LUAD tissues than in adjacent normal tissues, and elevated in A549, H1299, and PC9 cells as compared to Beas-2B control cells. In addition, CAP1 promoter was abnormally hypo-methylated in LUAD cells and tissues. Up-regulating CAP1 promoter methylation through the CRISPR-dCas9-Dnmt3a system which reduced CAP1 expression can induce apoptosis via the Bax/Bcl-2/Caspase-3 pathway, and inhibited migration and invasion. We also found that the methylation of the CAP1 promoter was regulated by Dnmt3a, Tet1, and/or Tet2.
conclusionUp-regulating CAP1 promoter methylation promotes apoptosis and inhibits migration and invasion of LUAD cells. This suggests that methylating the CAP1 promoter could be a potential therapeutic approach for early-stage LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.